Form DEF 14A NeoGenomics For: 6 April
- Investing.com
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
NeoGenomics Inc (NEO)
NeoGenomics Inc stock price live, this page displays NASDAQ NEO stock exchange data. View the NEO premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the NeoGenomics Inc real time stock price chart below.
What Is the NeoGenomics Inc Stock Price Today?
The NeoGenomics Inc stock price today is 8.18.
What Is the Stock Symbol for NeoGenomics Inc?
The stock ticker symbol for NeoGenomics Inc is NEO.
Is NEO the Same as $NEO?
$NEO is a common way to refer to the NeoGenomics Inc ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does NeoGenomics Inc Trade On?
NeoGenomics Inc is listed and trades on the NASDAQ stock exchange.
Is NeoGenomics Inc a Good Stock to Buy?
Determining whether NeoGenomics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current NeoGenomics Inc share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the NEO quote. (ISIN: US64049M2098)
What Is the NeoGenomics Inc Stock Price Today?
The NeoGenomics Inc stock price today is 8.18.
What Is the Stock Symbol for NeoGenomics Inc?
The stock ticker symbol for NeoGenomics Inc is NEO.
Is NEO the Same as $NEO?
$NEO is a common way to refer to the NeoGenomics Inc ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does NeoGenomics Inc Trade On?
NeoGenomics Inc is listed and trades on the NASDAQ stock exchange.
Is NeoGenomics Inc a Good Stock to Buy?
Determining whether NeoGenomics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current NeoGenomics Inc share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the NEO quote. (ISIN: US64049M2098)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
7.75
8.20
52 wk Range
4.72
13.74
Earnings results expected in 6 days
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
7.758.20
52 wk Range
4.7213.74
Key Statistics
Edit
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
NEO Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Price Target
14.19
Upside
+73.44%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Net income is expected to grow this year
- NeoGenomics Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- Form DEF 14A NeoGenomics For: 6 April
- Investing.com
- NeoGenomics Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro - NeoGenomics Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Strong Buy
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company offers molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients’ oncology programs covering discovery and commercialization. The company was founded in 2001 and is headquartered in Fort Myers, Florida.
NeoGenomics Inc SWOT Analysis
Financial Outlook | Analyst sets C$13.00 price target for Neo, reflecting confidence in the company's potential despite current profitability challenges and market uncertainties |
Market Dynamics | Delve into Neo's position in the volatile rare earths market, balancing geopolitical risks against increasing demand for critical materials in high-tech applications |
European Expansion | Explore Neo's new agreement with a major European automotive supplier, signaling growth potential in the lucrative electric vehicle market |
Strategic Crossroads | Neo Performance Materials faces pivotal decisions as it reviews strategic alternatives, potentially reshaping its future in the rare earths and advanced materials secto |
NeoGenomics Inc Earnings Call Summary for Q4/2025
- NeoGenomics reported Q4 2025 EPS of $0.06, beating expectations by 50%, with revenue reaching $190.17 million (11% YoY growth), though stock fell 3.34% in pre-market trading.
- The company projects 2026 revenue between $793-801 million, with adjusted EBITDA forecasted at $55-57 million and expected gross margin expansion of 100-120 basis points.
- Clinical and next-generation sequencing revenues showed strong growth of 16% and 23% respectively, with NeoGenomics maintaining a 25% market share in hematology testing.
- CEO Tony Zook expressed confidence in 'ending the year in a very strong position with accelerated growth opportunities,' highlighting the company's focus on precision oncology.
- The upcoming RaDaR ST launch is expected to contribute mid-single-digit millions to revenue, while the pharma segment recovery is cautiously projected for 2027.
Last Updated: 02/17/2026, 09:50 AM
Read Full TranscriptNeoGenomics investor slides for Q4/2025
Last Update: Feb 17, 2026
See full investor slides
Compare NEO to Peers and Sector
Metrics to compare | NEO | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNEOPeersSector | |
|---|---|---|---|---|
P/E Ratio | −9.7x | −24.2x | −0.4x | |
PEG Ratio | 0.27 | −0.24 | 0.00 | |
Price / Book | 1.2x | 1.2x | 2.6x | |
Price / LTM Sales | 1.4x | 4.2x | 3.2x | |
Upside (Analyst Target) | 75.9% | 44.9% | 45.4% | |
Fair Value Upside | Unlock | 10.0% | 7.0% | Unlock |
Analyst Ratings
6 Buy
6 Hold
0 Sell
Ratings:
12 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 14.19
(+73.44% Upside)
Earnings
Latest Release
Feb 17, 2026
EPS / Forecast
0.06 / 0.04
Revenue / Forecast
190.17M / 188.14M
People Also Watch
FAQ
What Is the NeoGenomics (NEO) Stock Price Today?
The NeoGenomics stock price today is 8.18 USD.
What Stock Exchange Does NeoGenomics Trade On?
NeoGenomics is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for NeoGenomics?
The stock symbol for NeoGenomics is "NEO."
What Is the NeoGenomics Market Cap?
As of today, NeoGenomics market cap is 1.05B USD.
What Is NeoGenomics's Earnings Per Share (TTM)?
The NeoGenomics EPS (TTM) is -0.84.
When Is the Next NeoGenomics Earnings Date?
NeoGenomics will release its next earnings report on Apr 28, 2026.
From a Technical Analysis Perspective, Is NEO a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
How Many Times Has NeoGenomics Stock Split?
NeoGenomics has split 2 times.
How Many Employees Does NeoGenomics Have?
NeoGenomics has 2500 employees.
What is the current trading status of NeoGenomics (NEO)?
As of Apr 22, 2026, NeoGenomics (NEO) is trading at a price of 8.18 USD, with a previous close of 7.96 USD. The stock has fluctuated within a day range of 7.75 USD to 8.20 USD, while its 52-week range spans from 4.72 USD to 13.74 USD.
What Is NeoGenomics (NEO) Price Target According to Analysts?
The average 12-month price target for NeoGenomics is 14.19 USD, with a high estimate of 17 USD and a low estimate of 12 USD. 6 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +73.44% Upside potential.
What Is the NEO Premarket Price?
NEO's last pre-market stock price is 8.40 USD. The pre-market share volume is 41,550.00, and the stock has decreased by 0.44, or 5.53%.
What Is the NEO After Hours Price?
NEO's last after hours stock price is 8.26 USD, the stock has decreased by 0.08, or 0.98%.
Industry Spotlight
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.